https://www.youtube.com/watch?v=kEGccyXSQAU
New one from Liz.
Full Video ► https://goo.gl/tHvTF5
BioViva ► http://bioviva-science.com
This week saw researchers announce a promising new approach to Parkinson’s by the use of cellular reprogramming. The team lead by Ernest Arenas used a cocktail of four transcription factors to reprogram support cells inside the brain.
The research team placed the reprogramming factors into a harmless type of lentivirus and injected them en masse into a Parkinson’s disease model mice. The viruses infected support cells in the brain known as astrocytes (a support cell that regulates the transmission of electrical impulses within the brain) which are present in large numbers. The lentiviruses delivered their four factor payload to the target cells changing them from astrocytes into dopamine producing neurons.
Within three weeks the first cells had been reprogrammed and could be detected, and after fifteen weeks there were abundant numbers of dopamine producing neurons present. This is good news indeed as it also confirms that once reprogrammed the cells remain changed and stable and do not revert back into astrocytes.
Continue reading “Reprogramming brain cells offers hope for Parkinson’s” »
Interest in rejuvenation biotechnology is growing rapidly and attracting investors.
- Jim Mellon has made an investment in Insilico Medicine to enable the company to validate the many molecules discovered using deep learning and launch multi-modal biomarkers of human aging
Monday, April 10, 2017, Baltimore, MD — Insilico Medicine, Inc, a big data analytics company applying deep learning techniques to drug discovery, biomarker development, and aging research today announced that it has closed an investment from the billionaire biotechnology investor Jim Mellon. Proceeds will be used to perform pre-clinical validation of multiple lead molecules developed using Insilico Medicine’s drug discovery pipelines and to advance research in deep learned biomarkers of aging and disease.
Everolimus heading for human clinical trials later this year to treat immune system decline.
The biotechnology company PureTech are moving towards human clinical trials with a new therapy that may slow down the aging process and combat age-related disease. The company has licensed two new drug candidates, derivatives of the drug Rapamycin, from pharmaceutical giant Novartis.
PureTech have recently announced a joint venture with Novartis called resTORbio and are moving to clinical trials of the new drugs later this year. The aim of the first test phase is to see if the new drug can rejuvenate the immune system of aged people a key reason why we lose the ability to resist diseases as we grow older.
Continue reading “New drug aimed at slowing aging heads to the clinic” »
For people in that area, and it may be worth while to try reaching out to them for funding for anti aging stuff.
Why is RAND opening a Bay Area office?
The San Francisco Bay Area is really at the center of technology and transformation. That’s also been a focus at RAND since our very first report, Preliminary Design of an Experimental World-Circling Spaceship, in 1946, which foretold the creation of satellites more than a decade before Sputnik.
Continue reading “Innovation in the Bay Area: Q&A with Nidhi Kalra” »
Technically, an animal could use RNA editing to change the nature of its proteins without completely altering the underlying DNA instructions. This makes the cephalopods’ ability to do it a very interesting phenomenon, but it’s unclear as to why the species requires this much RNA editing. Many of the edited proteins were found in the animals’ brains, which is why scientists think the editing and their brainpower could be linked.
More than any other species on earth, octopuses are particularly smart—they can solve puzzles, use tools, and communicate using color. Now scientists are saying they’re also capable of editing their RNA.
A team of scientists led by Joshua Rosenthal at the Marine Biological Laboratory and Noa Liscovitch-Braur and Eli Eisenberg at Tel Aviv University have discovered that octopuses and squid are capable of a type of genetic alteration called RNA editing. The process is rare among other species, leading scientists to believe that the cephalopods have evolved to follow a special kind of gene recoding.
Continue reading “These Species Can Recode Their Own Genetics” »
Some weird religious stories w/ transhumanism Expect the conflict between religion and transhumanism to get worse, as closed-minded conservative viewpoints get challenged by radical science and a future with no need for an afterlife: http://barbwire.com/2017/04/06/cybernetic-messiah-transhuman…elligence/ & http://www.livebytheword.blog/google-directors-push-for-comp…s-explain/ & http://ctktexas.com/pastoral-backstory-march-30th-2017/
By J. Davila Ashcroft
The recent film Ghost in the Shell is a science fiction tale about a young girl (known as Major) used as an experiment in a Transhumanist/Artificial Intelligence experiment, turning her into a weapon. At first, she complies, thinking the company behind the experiment saved her life after her family died. The truth is, however, that the company took her forcefully while she was a runaway. Major finds out that this company has done the same to others as well, and this knowledge causes her to turn on the company. Throughout the story the viewer is confronted with the existential questions behind such an experiment as Major struggles with the trauma of not feeling things like the warmth of human skin, and the sensations of touch and taste, and feels less than human, though she is told many times she is better than human. While this is obviously a science fiction story, what might comes as a surprise to some is that the subject matter of the film is not just fiction. Transhumanism and Artificial Intelligence on the level of the things explored in this film are all too real, and seem to be only a few years around the corner.
Continue reading “The Cybernetic Messiah: Transhumanism and Artificial Intelligence” »
